Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma  by Benamar, Mouadh et al.
EBioMedicine 10 (2016) 85–100
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch PaperInactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation
axis underlies the therapeutic efﬁcacy of pevonedistat in melanomaMouadh Benamar a, Fadila Guessous a, Kangping Du a, Patrick Corbett a, Joseph Obeid b, Daniel Gioeli c,
Craig L. Slingluff Jr b, Tarek Abbas a,d,e,⁎
a Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908, USA
b Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
c Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA
d Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA
e Center for Cell Signaling, University of Virginia, Charlottesville, VA 22908, USA⁎ Corresponding author at: Department of Radiation O
Charlottesville, VA 22908, USA.
E-mail address: ta8e@virginia.edu (T. Abbas).
http://dx.doi.org/10.1016/j.ebiom.2016.06.023
2352-3964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 9 May 2016
Received in revised form 13 June 2016
Accepted 15 June 2016
Available online 16 June 2016The cullin-based CRL4-CDT2 ubiquitin ligase is emerging as a master regulator of cell proliferation. CRL4-
CDT2 prevents re-initiation of DNA replication during the same cell cycle “rereplication” through targeted
degradation of CDT1, SET8 and p21 during S-phase of the cell cycle. We show that CDT2 is overexpressed
in cutaneous melanoma and predicts poor overall and disease-free survival. CDT2 ablation inhibited a
panel of melanoma cell lines through the induction of SET8- and p21-dependent DNA rereplication and se-
nescence. Pevonedistat (MLN4924), a speciﬁc inhibitor of the NEDD8 activating enzyme (NAE), inhibits the
activity of cullin E3 ligases, thereby stabilizing a vast number of cullin substrates and resulting in cancer cell
inhibition in vitro and tumor suppression in nude mice. We demonstrate that pevonedistat is effective at
inhibiting the proliferation of melanoma cell lines in vitro through the induction of rereplication-dependent
permanent growth arrest as well as through a transient, non-rereplication-dependent mechanism. CRISPR/
Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated
that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degrada-
tion of p21 and SET8 and is essential for melanoma suppression in nude mice. By contrast, pevonedistat-in-
duced transient growth suppression was independent of p21 or SET8, and insufﬁcient to inhibit tumor
growth in vivo. Pevonedistat additionally synergized with the BRAF kinase inhibitor PLX4720 to inhibit
BRAF melanoma, and suppressed PLX4720-resistant melanoma cells. These ﬁndings demonstrate that the
CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma
and suggest that a broad patient population may beneﬁt from pevonedistat therapy.
Research in Context: The identiﬁcation of new molecular targets and effective inhibitors is of utmost signif-
icance for the clinical management of melanoma. This study identiﬁes CDT2, a substrate receptor for the
CRL4 ubiquitin ligase, as a prognostic marker and therapeutic target in melanoma. CDT2 is required for mel-
anoma cell proliferation and inhibition of CRL4CDT2 by pevonedistat suppresses melanoma in vitro and in
vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4CDT2
substrates p21 and SET8. Pevonedistat also synergizes with vemurafenib in vivo and suppresses
vemurafenib-resistant melanoma cells. These ﬁndings show a signiﬁcant promise for targeting CRL4CDT2
therapeutically.











Melanoma is an aggressive cancer affecting approximately 80,000
patients per year in the USA, with poor prognosis in the metastatic
stage (Balch et al., 2009). It is the sixth most common fatal malignancyncology, University of Virginia,
. This is an open access article underaccounting for about 4% of all cancer-related deaths (Siegel et al., 2012).
At the molecular level, activating mutations in the serine/threonine ki-
nase BRAF (p.V600E) or NRAS (mostly p.Q61R or p.Q61K) occur in ama-
jority (60–70%) of cases (Davies et al., 2002; Davies and Samuels, 2010).
Both oncogenes activate the classical mitogen-activated protein kinase
(MAPK) pathway, but NRAS additionally activates the phosphatidyl-
inositol 3-kinase (PI3K) pro-survival pathway. The recent development
of inhibitors of oncogenic BRAF, such as vemurafenib and dabrafenib,
has offered signiﬁcant opportunities for the treatment of at least athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2010; Hersey et al., 2009; Sosman et al., 2012). The development of
therapeutic resistance however, represents major challenges that re-
quire the identiﬁcation of alternative therapeutic approaches and new
molecular targets and chemical inhibitors that can exert anti-melanoma
activity and can operate irrespective of the BRAF or NRAS mutational
status.
Polyubiquitylation leading to proteolytic degradation by the 26S
proteasome is involved in all aspects of cell physiology. The highly
coordinated process ensures the selective and timely turnover of
proteins, thereby controlling cellular activity and maintaining cell
and tissue homeostasis (Glickman and Ciechanover, 2002). The
cullin 4 RING E3 ubiquitin ligase (CRL4) is a master regulator of ge-
nome stability and orchestrates a variety of physiological processes,
particularly those related to chromatin regulation (Jackson and
Xiong, 2009). Along with the substrate receptor CDT2 (also known
as DCAF2, DTL/RAMP), the CRL4CDT2 ligase promotes the ubiquitin-
dependent degradation of several proteins essential for cell cycle
progression as well as for DNA replication and repair (Abbas and
Dutta, 2011; Abbas et al., 2013). One of the main functions of CRL4-
CDT2 is to prevent re-initiation of DNA replication (rereplication),
both during S-phase of the cell cycle and following DNA damage,
through the ubiquitylation and degradation of the replication licens-
ing protein CDT1 (unrelated to CDT2), the CDK inhibitor p21, and the
histonemethyltransferase SET8 (Abbas and Dutta, 2011; Abbas et al.,
2013). DNA rereplication is deleterious to cells and promotes cellular
senescence and apoptosis due to replication fork stalling and the ac-
cumulation of toxic replication intermediates.
Cullin-dependent E3 ligases, including CRL4, are activated by NEDD8
modiﬁcation, which is catalyzed by an enzyme cascade system similar
to ubiquitylation (Merlet et al., 2009). Pevonedistat (MLN4924), an in-
hibitor of the NEDD8-activating enzyme (NAE), induces cytotoxicity in
a variety of cancer cell types in vitro and in preclinical mouse models
(Jazaeri et al., 2013; Lin et al., 2010; Soucy et al., 2009; Wei et al.,
2012). It is currently in clinical trials for hematologic (NCT00722488,
NCT00911066) and solid malignancies including melanoma
(NCT01011530), but its effects on melanoma cells have not been
thoroughly examined. There is also little to no preclinical data on
pevonedistat efﬁcacy in the context of the various genetic mutations as-
sociated with melanoma or resistance to front line therapies (Garcia et
al., 2014; Tan et al., 2013). Consistentwith its activity as a general inhib-
itor of protein neddylation, pevonedistat was shown to inhibit multiple
signal transduction pathways in addition to inhibiting cullin-mediated
signaling, including the NFκB, AKT and the mTOR signal transduction
pathways (Godbersen et al., 2014; Gu et al., 2014; Li et al., 2014a; Li et
al., 2014b; Lin et al., 2010; Milhollen et al., 2011; Milhollen et al.,
2010; Soucy et al., 2009). Although pevonedistat exerts these wide in-
hibitory activities, it remains unclear which, if any, mediates its anti-
tumor activity.
We here show that CDT2 is frequently overexpressed in melano-
ma, and its elevated expression predicts poor overall and disease-
free survival. CDT2 knockdown or deletion inhibits the proliferation
of melanoma cells in vitro through the induction of rereplication and
senescence, and via a mechanism that is dependent on the stabiliza-
tion of the CRL4CDT2 substrates SET8 and p21. Pevonedistat exerts
signiﬁcant anti-melanoma activity, irrespective of the BRAF muta-
tional status, and through the induction of SET8- and p21-dependent
rereplication and senescence. In vivo studies using melanoma cells
with hypomorphic expression of p21 or SET8 show that both of
these proteins are required for the anti-melanoma efﬁcacy of
pevonedistat, demonstrating that inhibition of the CRL4CDT2-SET8/
p21 degradation axis is the primary mechanism by which
pevonedistat inhibits melanoma. Finally, we show that pevonedistat
synergizes with the BRAF kinase inhibitor PLX4720 to suppress BRAF
mutant melanoma in vivo, and suppresses PLX4720-resistant mela-
noma cells.2. Materials & Methods
2.1. Cell Culture and Reagents
VMM39, VMM1, and VMM18 human melanoma cell lines were
established from metastatic lesions of patients at the University of Vir-
ginia (IRB #5202, by CLS). DM93, DM331, DM13 and SLM2 melanoma
cell lines had been established frommetastatic lesions by Dr. H.F. Seigler
atDukeUniversity (Hogan et al., 2005; Huntington et al., 2004; Kittlesen
et al., 1998; Molhoek et al., 2008; Slingluff et al., 1993; Yamshchikov et
al., 2001; Yamshchikov et al., 2005). SK-MEL-2 and SK-MEL-28melano-
ma cells were established in Memorial Sloan Kettering Cancer Center
and obtained from the American Type Culture Collection (ATCC,Manas-
sas, VA). All melanoma cells were grown in RPMI media supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S).
PIG1 and PIG3V melanocytes were described before (Le Poole et al.,
2000) and maintained in Media 254 containing 1% of human melano-
cyte growth supplement (HMGS), 5% FBS and 1% (P/S). All cells were
grown at 37 °C in 5% CO2. Tissue extraction reagent I was obtained
from Invitrogen (Carlsbad, CA). Propidium iodide, 7-AAD and BrdU kit
were purchased from BD Biosciences (San Diego, CA). Vector's
ImmPRESS polymer kit for TMAs immunostaining was obtained from
Vector laboratories (Burlingame, CA). Pevonedistat and vemurafenib
(PLX4032) were purchased from Active Biochem (Wan Chai, Hong
Kong), and were dissolved in DMSO and used at the indicated doses.
2.2. Cell Lysis, SDS-PAGE and Immunoblotting
Melanoma cells were lysed with RIPA lysis buffer (50 mM Tris,
pH 8.0; 150 mM NaCl, 1% NP-40; 0.5% sodium deoxycolate; 0.1% SDS;
1 mM Benzamidin -HCl; 0.5 μg/ml Leupeptin; 0.5 μg/ml Aprotinin;
1 μg/ml pepstatin; 20 mM NaF; 20 mM Na3VO4), and equal amounts
of protein were electrophoretically separated in a polyacrylamide 8–
12% gel (BioRad, Hercules, CA), trans-blotted to a nitrocellulose mem-
brane, and incubated overnightwith primary antibodies at 4 °C. The fol-
lowing antibodies were used: anti-p21 (C19), anti-p27 (C19), anti-p53
(DO-1), and anti-tubulin (10D8) were purchased from Santa Cruz (Cal-
ifornia). Antibodies against SET8, CHK1, CHK2, p-CHK1 (S375), p-CHK2
(T68), H2AX and p-H2AX (γH2AX; T139), and PARP were purchased
from Cell Signaling (Danvers, MA). Anti-Cul3 was purchased from
Bethyl Laboratories (Montgomery, TX). Anti-CDT1 and anti-CDT2 anti-
bodies were described before (Abbas et al., 2010). The immunoblot sig-
nals were detected by enhanced chemiluminescence. For melanoma
xenografts, tumors were isolated, washed three times with cold PBS
and frozen at −80 °C until use. Frozen specimens were grinded in a
dry-iced mortar and subsequently lysed in 2× volume of tissue extrac-
tion reagent I, supplemented with protease and phosphatase inhibitors
as stated above. Tissue lysates were probed for different proteins by im-
munoblotting following the procedure described above.
2.3. RNA Interference (siRNA)-Mediated Gene Silencing
si-RNA transfections were performed using lipofectamine
RNAimax according to the manufacturer's protocol (Invitrogen,
Carlsbad, CA). Cells were seeded at 30% conﬂuency and transfected
with the individual siRNAs (10 nM each) in RPMImedia supplement-
ed with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin
(P/S). In co-knockdown experiments, DM93 or VMM39 cells were
transfected with the individual siRNAs (10 nM each with 10 nM con-
trol siGL2-for normalization) or siRNAs targeting CDT1, SET8 or p21
along with siRNA targeting CDT2 (10 nM each – total 20 nM siRNAs).
Control cells were transfectedwith 20 nM si-GL2. Cells were harvest-
ed 72 h post-transfection for cell cycle analysis or at 96 h for β-gal
staining. The following siRNAs were used (sense strand): si-GL2:
5′-AACGUACGCGGAAUACUUCGA-3′; si-CDT2: 5′-GAAUUAUACUGC
UUAUCGA-3′, si-CDT1: 5′-AACGUGGAUGAAGUACCCGAC-3′; si-
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GCCUGGACUG-3′; si-Geminin: 5′-UGCCAACUCUGGAAUCAAA-3′. si-
EMI1 were described previously (Machida and Dutta, 2007).
2.4. Gene Targeting by CRISPR/Cas9
Single guide-RNAs (sgRNAs) targeting the DTL (sg-CDT2-1 and
sg-CDT2), SET8 and CDKN1A genes were cloned into pX330 vector
containing a human codon-optimized SpCas9 endonuclease
(Addgene #42230) using BbsI restriction enzyme cutting sites, and
transfected in the various cell lines. After puromycin selection, cells
were seeded to obtain single colonies. Genomic DNA was extracted
using 100 mM NaCl, 50 mM Tris-HCl pH 7.0, 5 mM EDTA and 1%
SDS. Genotyping was performed using PCR ampliﬁcation of genomic
DNA using the following forward and reverse primer sets, respec-
tively. For CDT2: 5′-TGTTGTGAGAGGCGCAAGCTGC-3′ and 5′-
GGTCGGAGGTGGCGTGTGTTTC-3′; for SET8: 5′-GTCTTTCCCCCACC
TCCGCCTG-3′ and 5′-CTTTTTTCGGGGGGCCTGTTTGC-3′; for p21: 5′-
TCACCTGAGGTGACACAGCAAAGC-3′ and 5′-GGCCCCGTGGGAAG
GTAGAGCTT-3′. Targets of the various sgRNAs are as follows: For
DTL (CDT2): 5′-GCACCGAATTGAAGAGCATC-3′ (for sg-CDT2-1); and
5′-CATTTCTCAGGACGCCAAGC-3′ (for sg-CDT2-2); for SET8: 5′-
ACGGAGCGCCATGAAGTCCG-3′; for CDKN1A: 5′- GCGCCATGT
CAGAACCGGCT-3′. Insertions/deletions (Indels) identiﬁcation was
performed using Surveyor Mutation Detection Kit according to the
manufacturer's protocol (Integrated DNA Technologies, CA). For se-
quencing, PCR ampliﬁed gene products were cloned into Topo TA
Vector using TOPO TA cloning Kit according to the manufacturer's
protocol (Invitrogen, CA) and transformed into DH5α. Plasmids
were retrieved by the QIAprep Spin Miniprep Kit (Qiagen) and con-
ﬁrmed by sequencing (Euroﬁns Scientiﬁc).
2.5. Cell Proliferation/Viability Assays and Washout Experiments
Proliferation/viability of cultured cells was measured by CellTiter96
Non-radioactive cell proliferation assay (Promega; Madison, WI). Brief-
ly, various wild type and mutant BRAF melanoma cells were seeded in
96 well plates and treated with pevonedistat, vemurafenib or the com-
bination pevonedistat and vemurafenib at various concentrations. Con-
trol cells were treated with DMSO. 96 h following treatment, cells were
stained with the dye solution according to the manufacturer's protocol.
Absorbance was recorded at 570 nm and growth curves were
established. To test the effect of transient exposure of melanoma cells
to pevonedistat on rereplication and growth inhibition, we conducted
the washout experiments wheremelanoma cells or PIG3Vmelanocytes
were treated with 1 μM pevonedistat for different times (4, 8, 12 and
24 h) before the drug was washed out by washing the cells 2× with
PBS, and adding drug-free fresh growthmedia to cells. Cellswere count-
ed every 24 h by Countess Automated Cell Counter (Invitrogen), and
harvested at the indicated times for PI staining and FACS analysis (cell
cycle proﬁle) or for immunoblotting.
2.6. Clonogenic Survival Assays
Cell survival following CDT2 depletion or pevonedistat treatment
was assessed by clonogenic survival assay, preformed in triplicates.
72 h following transfection with si-GL2 or si-CDT2, cells were
trypsinized, counted and seeded in 60 mm dishes. For pevonedistat
treatments, cells were counted and seeded in 60mmdishes and treated
24 h later with various doses of pevonedistat or with DMSO. Cells were
cultured for two weeks and were subsequently washed in cold PBS,
ﬁxed in cold methanol for 10 min and stained with crystal violet
(0.5%) for 10 min. Plates were washed with water, dried and pictures
were captured using Imagelab software (BioRad). Quantiﬁcation of col-
onies was performed using QuantityOne software (BioRad). Results arerepresented as mean ± s.e.m. of triplicates normalized to the corre-
sponding DMSO-treated or si-GL2 transfected controls.
2.7. Senescence-Associated β-galactosidase Assays
Senescence was monitored using β-galactosidase (β-gal) staining.
Following the various treatments, cells were washed twice with PBS,
ﬁxed with 2% formaldehyde/0.2% gluteraldehyde in PBS for 15 min at
room temperature, and washed 2× with PBS. The cells were stained
with fresh X-Gal solution (1 mg/ml X-gal, 40 mM C6H8O7·H2O, 5 mM
K3Fe(CN)6, 5 mM K4Fe(CN)6·3H2O, 150 mM NaCl, and 2 mM
MgCl2·6H2O in PBS) for 3–12 h at 37 °C in the dark. Cells were washed
3× in PBS andﬁxedwith 100%methanol for 5min at room temperature.
Bright ﬁeld blue color images were takenwith an AMG EvosXL Core Im-
ager/camera microscope, counting at least 100 cells from at least 3
ﬁelds.
2.8. Flow Cytometry Analysis
The effects of pevonedistat, vemurafenib and/or silencing of various
cell cycle-associated proteins by siRNA on cell cycle distribution and
rereplication were assessed by propidium iodide staining and ﬂow cy-
tometry of asynchronous melanoma cultures. Synchronization of cells
was not employed to avoid bias and to be able to measure the impact
of these perturbations on proliferating cancer cells. Brieﬂy, asynchro-
nous melanoma cell lines were treated with pevonedistat or
vemurafenib, or transfected with si-CDT1, si-CDT2, si-SET8, si-p21, si-
geminin, si-EMI1 or si-GL2 for a time ranging from 24 to 96 h. Cells
were washed with cold PBS, harvested, and ﬁxed in 70% (v/v) ethanol.
Cells were subsequently treated with 20 μg of DNase-free RNase and
stainedwith propidium iodide according to instructions of themanufac-
turer. Samples were analyzed on a FACscan (Becton Dickinson) and G0-
G1, S, and G2-M fractions were segmented, and apoptotic (sub-G1 DNA
content) and rereplicating (NG2/M DNA content) fractions were deter-
mined using FlowJo and ModFit softwares.
2.9. Bromodeoxy Uridine (BrdU) Staining and Flow Cytometry
The effects of pevonedistat and/or silencing of cell cycle-associated
proteins on cell cycle distribution or rereplication were assessed by
ﬂow cytometry according to the manufacturer's instructions. Different
melanoma lines were transfected with si-GL2, si-CDT2, si-CDT1, si-
SET8, si-p21 or si-geminin for a time ranging from 24 to 96 h. At the
end of treatment, cells were pulsed with BrdU (10 nM) for 1 h in the
dark prior to harvesting. Cells were washed with PBS and staining solu-
tion before the ﬁxation and permeabilization steps according to the
manufacturer's instructions. Cells were subsequently stained with
anti-BrdU antibody solution for 20 min at room temperature, washed
and stained with 7-AAD solution for 30 min at 4 °C. The cells were re-
suspended in 1 ml of staining buffer and kept overnight at 4 °C before
analysis. Samples were analyzed on a FACscan (Becton Dickinson),
and different phases of the cell cycle were determined using FlowJo
and ModFit softwares.
2.10. Staining and Analysis of Melanoma Tissue Microarray (TMA)
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue blocks were re-
trieved from archives of the Department of Pathology, University of Vir-
ginia. Use of human tissues was approved by the UVA Institutional
Review Board (protocol 10598). Hematoxylin and eosin (H&E) slides
from each block were reviewed by a pathologist (JS) to identify tumor
areas. TMAs were constructed with 1.0-mm diameter tissue cores
from representative tumor areas from the FFPE tissue blocks, trans-
ferred into a recipient parafﬁn block using a semi-automated tissue
array instrument (TMArrayer; Pathology Devices). Quadruplicate or
triplicate tissue cores were taken from each specimen, resulting in 9
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each. Control tissues from spleen, liver, placenta, and kidney were in-
cluded in each TMA block (not shown). Multiple 4 μm sections were
cut for H&E and immunohistochemical staining. The human melanoma
tissuemicroarray (TMA)was evaluated for expression of CDT2 and Ki67
by immunohistochemistry. Details of this TMA have been reported pre-
viously (Erdag et al., 2012). These arrays included surgical specimens of
human melanoma. Protein expression patterns of CDT2 and Ki67 were
assessed in 138 tumor specimens in the TMA. Three nevi were used as
a control. Antigen-retrieval step was performed at low pH 0.01% citric
acid for 20 min at 100 °C. Endogenous peroxidase was blocked using
Vector's Bloxall (SP-6000) for CDT2 detection and 0.3% Hydrogen per-
oxide for Ki67 detection; for 10 min; prior to serum blocking for
20 min, at room temperature. Incubation with CDT2 primary antibody
(Abbas et al., 2008) (1:100 dilution) was performed at room tempera-
ture for 30 min. Staining with Ki67 primary antibody (Vector laborato-
ries; 1:50 dilution) was performed overnight at 4 °C. Omitting the
primary antibody served as a negative control for the staining. The Sec-
ondary antibody (SK-4200 ImmPRESS reagent; 1:500 dilution) was
used for 30min followed by substrate AEC (Vector laboratories) incuba-
tion for 20min, at room temperature as per the kit's instructions. Diami-
nobenzidine was utilized as the ﬁnal chromogen and hematoxylin as
the nuclear counterstain. Staining frequency of CDT2 and Ki67 were
quantiﬁedmanually by counting the number of positively stained nuclei
in an average of three ﬁelds per core. The frequency is calculated by di-
viding the number of positive staining over the total number of cells in
the same ﬁelds.
Immunohistochemical staining for BRAFmutation (V600E)was per-
formed at the University of North Carolina, using Leica's Bond
autostainer (Leica Biosystems, Nussloch, Germany) and the BRAF
V600E antibody (Spring Bioscience, clone VE1, dilution 1:400). Muta-
tional status is assessed by the presence or absence of staining in each
core. Tumors with borderline staining and those with discrepant ex-
pression in between cores were excluded. The consensus value of the
2–4 representative cores from each tumor/patient sample arrayed was
used for scoring and statistical analyses. TMA slides were quantiﬁed
using Aperio ImageScope V11.2.
2.11. Kaplan-Meier Plot Analysis
Publicly available TCGA data at cBioPortal (Cerami et al., 2012; Gao
et al., 2013) was used to plot Kaplan-Meier plots on tumors divided
into two groups based on level of CDT2 expressed as a Z-score
(Collisson et al., 2014; Taylor et al., 2010; Weinstein et al., 2014).
2.12. Tumor Xenograft Studies
Animalswere housed andhandled in accordancewith the guidelines
of the Animal Care and Use Committee (ACUC) of the University of Vir-
ginia. The effect of pevonedistat on melanoma growth was tested in
ﬂank xenograft models. Foxn1nu (20–25 g body weight, 4–5 weeks old
females) athymic nude immune-deﬁcient mice (Harlan laboratories)
were used in this study. Pevonedistat was dissolved in sterile 10%
DMSO containing PBS (stock 1 mM) and stored in −20 °C until use.
2 × 106 of DM93, VMM39, SLM2, DM331 or SK-MEL-24 melanoma
cells were implanted in both ﬂanks of immune-deﬁcient mice (n= 12
mice per group) and tumor growthwasmonitored until reaching an av-
erage volume of 150–200 mm3. Mice were randomized into groups for
treatment. Animals were administered 0.2 mL pevonedistat solution
(30 or 60mg/kg bodyweight as indicated) intraperitoneally on a sched-
ule of two cycles of ﬁve-day treatment followed by ﬁve treatment-free
days, for a total of 3 weeks, or more as indicated. Control animals
were treated with an equal volume of sterile vehicle (10% DMSO in
PBS). Where indicated, mice received control rodent diet, or diet with
417 mg/kg PLX4720 (Research Diets, Inc. New Brunswick, NJ). Tumors
were measured with an electronic caliper every other day for 3 weekspost-drug injection. Animal weight was recorded once a week to detect
any weight loss due to the toxicity of drug treatment or tumor burden.
At the endof treatment, animalswere euthanized and tumors harvested
for further processing. The results shown are mean tumor volumes at
the indicated time ± s.e.m.; *p b 0.05, **p b 0.01, ***p b 0.001.
2.13. Statistical Analysis
All experiments were performed in triplicates. Numerical data were
expressed as mean ± standard deviation (SD). Where applicable, data
are presented as the mean ± s.e.m. Two group comparisons were ana-
lyzed by two-sided Student's t-test. P-values were determined for all
analyses and p b 0.05 was considered signiﬁcant. Synergy was deter-
mined using the Bliss model of independence (Bliss, 1939; Fitzgerald
et al., 2006). For correlations, a Spearman correlation was used and p-
values b0.05 were considered statistically signiﬁcant.
3. Results
3.1. CDT2 Is Overexpressed in Melanoma and Its Elevated Expression Pre-
dicts Poor Patient Outcome
Melanoma is a malignancy in which genetic predisposition is, to a
large extent, associated with mutations in genes controlling DNA repli-
cation and/or proliferation (e.g. CDKN2A), but thus far most successful
targeted drugs have focused on the oncogenic drivers in theMAP Kinase
pathway (Lovly and Shaw, 2014). We suspected that vulnerabilities to
drugs targeting the DNA replication machinery would be identiﬁed,
and thus, searched gene expression databases for alterations in genes
controlling DNA replication in melanoma. Using mRNA expression in a
publicly available database of cutaneous melanomas (Talantov et al.,
2005), we found that CDT2 is overexpressed in 84% of melanomas com-
pared with normal skin or with benign skin nevi (Fig. 1a and b). CDT2
was also overexpressed in breast, cervical, gastric, lung, pancreatic,
and brain malignancies (Figure S1). CDT2 overexpression in melanoma
was speciﬁc, as we did not detect changes in the expression of Cul4A,
Cul4B, RBX1, or 4 other DCAFs i.e. DDB2, VPRBB1, DWR68 and DCAF8
(Figure S2a).
We also examined the expression of CDT2 in melanoma using data
obtained from The Cancer Genome Atlas (TCGA) project comprised of
471 primary and metastatic melanomas from 468 patients, available at
cBioPortal (Cerami et al., 2012; Gao et al., 2013). Kaplan-Meier plots re-
vealed that tumors with higher CDT2 expression correlated with signif-
icantly lower probability of overall and disease-free survival (Fig. 1c and
d). DNA sequences are available for a subset (~60%, 278 samples) of this
data set, which exhibited similar correlations (Figure S2b and S2c).
Analysis of the BRAF orNRASmutations in these tumors showedmodest
increase in the probability of overall survival in patients with BRAFmu-
tations, and no signiﬁcant correlations in patients with NRASmutations
(Figure S2d and S2e). Further analysis demonstrated that 72% of tumors
with high CDT2 expression harbored either BRAF (31%) or NRAS (41%)
mutations (Fig. 1e). This was not signiﬁcantly different in low CDT2 ex-
pressing tumors with 74% of these tumors containing BRAF (52%) or
NRAS (21%) mutations. Gene co-expression analysis demonstrated
that CDT2 elevated expression correlated with the expression of several
E2F1 target genes (data not shown), suggesting that CDT2 overexpres-
sion inmelanomamay be due to increased E2F1 transcriptional activity,
which has been shown to promote transcription from the CDT2 (DTL)
promoter (Nakagawa et al., 2008).
We next examined CDT2 protein expression in a human tissue mi-
croarray (TMA) comprising 138 melanoma specimens from 100 pa-
tients (42 female, 58 male, ages 23–90; mean 59 ± 16). These include
8 patients with large primary cutaneous melanoma and 92 with one
or more metastatic melanomas. CDT2 protein was predominantly nu-
clear and signiﬁcantly elevated in 84.7% of all melanomas (117/
138), whereas CDT2 was not detectable in non-malignant
Fig. 1. CDT2 is overexpressed in primary and metastatic cutaneous melanoma and is a negative prognostic factor (see also Figures S1 and S2). a–b. CDT2 mRNA expression is elevated in
melanoma compared to normal skin (a) or benign nevi (b). c–d. Kaplan–Meier plot of overall survival (c) or disease-free survival (d) for the human skin cutaneous melanoma (SKCM)
from TCGA stratiﬁed by CDT2 median expression level. High: CDT2 level N 0.23z and Low: CDT2 level b 0.23z. EXP: the CDT2 expression level z-score cut-off used for dividing high
from low expressers. n = number of patients in that group. M = median survival in months of that group (for overall survival) or median disease-free survival in months (for disease-
free survival). e. Pie chart depicting the percentage of BRAF and NRAS mutations (or both) in a subset of high and low CDT2 expressing melanoma samples (in c–d) for which
mutational analysis is available. f. Representative images of CDT2 staining in melanoma TMA or in melanocytic sample. Scale bar, 100 μm. g. CDT2 composite expression score in
cutaneous melanoma TMA (138 melanoma specimens from 100 patients) compared to non-malignant melanocytes. ***p b 0.001, calculated using Student's t-test. h. Relative CDT2
composite expression score in metastatic melanoma compared to primary melanoma. *p b 0.05. i. Correlation between elevated CDT2 composite expression with Ki67 staining in the
TMA analyzed in (g). j. CDT2 composite expression score in cutaneous melanoma with or without BRAFmutations in the TMA analyzed in (g). ns: non-signiﬁcant.
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Fig. 2. Depletion of CDT2 inhibits melanoma cell proliferation through the induction of rereplication and senescence (see also Figures S3 and S4). a. Impact of CDT2 depletion by siRNA on the
proliferation of DM93 melanoma cells. Data represent the average of three independent experiments ± S.D. (error bars). Inset: Western blot of cell lysates extracted from transfected DM93
cells and probed with the indicated antibodies. b. Representative phase contrast images depicting morphological changes in DM93 depleted of CDT2. c. Cell cycle distribution of control or si-
CDT2 transfected DM93 cells as demonstrated by propidium iodide staining and FACS analysis. d. BrdU incorporation and FACS analysis demonstrating the BrdU incorporation and cell cycle
distribution of DM93 cells following CDT2 depletion by siRNA. e. Graph showing the number of cells from the indicatedmelanoma lines 96 h following transfectionwith si-CDT2 or control si-
GL2. 4 × 106 cells of each cell line were seeded at the beginning of transfection. Data represent the average of three independent experiments ± S.D. (error bars). f. Same as in (e) except cells
were harvested at 72 h post-transfection and analyzed by FACS for DNA content. Data represent the average of three independent experiments ± S.D. g. Immunoblotting of protein lysates
extracted from control or CDT2-depleted DM93 cells for the indicated time points and probed for the indicated proteins. Tubulin is loading control. C-PARP: cleaved PARP protein. h.
Representative images of control or CDT2-depleted DM93 cells and stained with β-gal to detect senescence. i. The percentage of melanoma lines undergoing senescence (β-gal staining)
96 h following transfection with control (si-GL2) or CDT2 siRNA (siRNA). Data represent the average of three independent experiments ± S.D. *p b 0.05 **p b 0.01, ***p b 0.001, calculated
using Student's t-test. ns: non-signiﬁcant. j. Immunoblotting of lysates extracted from DM93 cells transfected with the indicated si-RNA and probed with the indicated antibodies. k.
Percentage of rereplicating cells following the indicated treatment as determined by BrdU labeling and FACS analysis (shown in Figure S4a). Data represent the average of three
independent experiments ± S.D. *p b 0.05, calculated using Student's t-test. l. Percentage of senescent DM93 cells (β-gal staining) treated with the indicated si-RNA. Representative images
are shown in Figure S4c. Data represent the average of three independent experiments ± S.D. **p b 0.01, ***p b 0.001, calculated using Student's t-test.
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signiﬁcantly higher in metastatic melanomas compared to primary
tumors (Fig. 1h). Analysis of Ki67 staining demonstrated a statistical-
ly signiﬁcant correlation between CDT2 and Ki67 staining (r=0.447,
p b 0.01) (Fig. 1l and Figure S2f). In this in situ analysis, we did not ob-
serve correlation between CDT2 expression and the BRAFmutational
status, disease stage or with lymphocytic inﬁltration, nor did we ﬁnd
correlationwith other parameters such as age, tissue type, gender, or
patient survival (Fig. 1j, Figure S2g and S2h, and data not shown).
The lack of correlation with patient survival in this dataset can be ex-
plained by the small sample size and by the fact that these tumors
were mostly metastatic. Together, these results demonstrate that
CDT2 expression is elevated in melanoma and serves as a negative
prognostic marker for the disease.
3.2. CDT2 Is Required for Melanoma Cell Proliferation
Although CDT2 is overexpressed in melanoma and in other cancers,
it is not likely to function as a classical oncogene. Instead, it appears to
act as a cancer-associated gene towhich cancer cells become “addicted”.
This is reminiscent to the secondary physiological changes that stress
cellular capacity for survival as a consequence of oncogenic activation,
common in melanoma and in other cancers; the so called “non-onco-
gene addiction” (Luo et al., 2009). We hypothesized that CDT2 is
overexpressed in melanoma cells to alleviate replication stress that
may be induced bymelanoma oncogenes. To test this hypothesis, we si-
lenced the expression of CDT2 by siRNA in a panel of melanoma lines
with various genetic mutations including the BRAF mutant DM93 cells
(Table S1). Depletion of CDT2 by siRNA (Fig. 2a and Figure S3a) sup-
pressedmelanoma cell proliferation and inducedmorphological chang-
es associated with rereplication; ﬂattening of cells and increase in
nuclear size (Fig. 2b and e). Flow cytometry analysis conﬁrmed the in-
crease in cells with N4 N DNA content, the extent of which varied
from cell line to cell line (Fig. 2c–f). We also detected a small but
reproducible increase in cells with sub-G1 DNA content (~5% on
average), indicative of apoptosis (Fig. 2c). Bromodeoxy uridine (BrdU)
incorporation and FACS analysis further illustrated that CDT2 knock-
down resulted in rereplication (~57%) during the same cell cycle
(Fig. 2d). DNA rereplication, morphological changes and suppression
of proliferation were also observed in 5 melanoma lines, including the
VMM39 cells with NRAS and PDGFRA activating mutations, following
the deletion of CDT2/DTL gene using CRISPR/Cas9 and two different sin-
gle guide RNAs (sg-RNAs) that target two different regions in exon 1 of
the CDT2 gene (Figure S3b–S3e).
CDT2 knockdown in DM93, and in other melanoma cells, increased
the steady state level of the CRL4CDT2 ubiquitylation substrates SET8
and p21, but elevated CDT1was only noted in some, but not all, melano-
ma lines (Fig. 2g and Figure S3a). This was associated with spontaneous
DNA damage (increased γH2AX), induction of DNA damage checkpoint
(phosphorylation of the checkpoint proteins CHK1 and CHK2), senes-
cence (β-galactosidase (β-gal) staining), as well as a small increase in
apoptosis (PARP cleavage) (Fig. 2g–i and Figure S3a). Thus, CDT2 deple-
tion or deletion inhibits melanoma with various genetic mutations and
this is accompanied by DNA rereplication, spontaneous DNA damage
and senescence.
3.3. SET8 and p21 Promote Rereplication and Senescence in CDT2-Depleted
Melanoma Cells
To investigate the mechanism by which CDT2 depletion induces
rereplication and senescence in melanoma cells, we co-knockdown, by
siRNA, the expression of various substrates of CRL4CDT2 previously impli-
cated in promoting DNA rereplication (Abbas and Dutta, 2011; Abbas et
al., 2013) along with CDT2 in DM93 or in VMM39 cells. Knockdown of
CDT1 prevented both rereplication and senescence induced by CDT2 de-
pletion, but increased the percentage of cells in G1 and decreased S-phase cells (Fig. 2j–l, Figure S4, and data not shown), suggesting that inhi-
bition of rereplication is secondary to cell cycle block in G1. Depletion of
SET8 or p21 on the other hand, completely suppressed si-CDT2-induced
rereplication, and senescence without signiﬁcantly impacting cell cycle
distribution (Fig. 2j–l and Figure S4). Thus, CDT1, SET8 and p21 are all
required for si-CDT2-induced rereplication and senescence, but CDT1
appears to be required primarily for entry into S-phase.
To examine the role of CDT1 further, we depleted variousmelanoma
lines (DM93, VMM39 or VMM18) of geminin, an inhibitor of CDT1
whose depletion induces rereplication in a number of cancer cell lines
(Zhu and Depamphilis, 2009). Interestingly, although si-geminin efﬁ-
ciently induced rereplication in the U2OS osteosarcoma cells and in
the Cal27 squamous cell carcinoma cells, it failed to do so in melanoma
cells (Fig. 3a–c). Depletion of EMI1, an inhibitor of the APC ubiquitin li-
gase whose depletion results in the ubiquitin-dependent proteolysis of
geminin and cyclin A (Machida and Dutta, 2007), on the other hand, in-
duced robust rereplication in melanoma cells (Figure S5a–S5c). Thus,
cyclin A, a cofactor required for CDT1 ubiquitylation via the SCFSKP2
ubiquitin ligase in S-phase (Abbas and Dutta, 2011; Abbas et al.,
2013), appears to restrain CDT1 activity in melanoma cells. Consistent
with this hypothesis, overexpression of SCFSKP2-resistant mutant of
CDT1 (CDT1ΔCY), but not CRL4CDT2-resistant mutant (CDT1ΔPIP; (Senga
et al., 2006)), in DM93 induced rereplication more robustly than wt
CDT1 (Fig. 3d, e, and Figure S5d and S5e). Thus, in melanoma cells, the
steady state level of CDT1 is regulated primarily by cyclin A-mediated
and CRL1SKP2-dependent pathway.
Unlike the case for CDT1 however, the stable overexpression of wt
SET8 (or p21) in DM93 or VMM39 cells did not induce rereplication
(Fig. 3f, g, Figure S5f, and data not shown). In contrast, expression of
SET8 mutant protein that cannot associate with PCNA (SET8ΔPIP) and
is thus resistant to CRL4CDT2 degradation (Abbas et al., 2010) induced
rereplication in both lines, and this required SET8 catalytic activity
(Fig. 3f–g, and Figure S5f–S5h). We noted that the catalytically inactive
mutant of SET8ΔPIP (SET8ΔPIP-CD) was less stable than the catalytically
active protein (Fig. 3f), and its overexpression from a higher titer virus
relative to catalytically active SET8ΔPIP did not induce rereplication ei-
ther (Figure S5g and S5h). Ectopic expression of CRL4CDT2-resistant
p21 protein (p21ΔPIP; (Abbas et al., 2008)) on the other hand, was asso-
ciated primarily with growth arrest in early- andmid S-phase (Fig. 3f, g,
and Figure S5f). Simultaneous expression of SET8ΔPIP and p21ΔPIP
caused more rereplication in DM93 (~46% compared to ~27% with
SET8ΔPIP alone), but not in VMM39 cells (Fig. 3f–g, and Figure S5f).
The lack of additive effects in VMM39 cells can be explained by the ro-
bust intra-S-phase cell cycle arrest caused by p21ΔPIP expression in
this line, preventing further rereplication. Finally, the expression of cat-
alytically active SET8ΔPIP or p21ΔPIP induced senescence in bothmelano-
ma cell lines (Fig. 3h and i). Thus, deregulated SET8 expression appears
to be both required and sufﬁcient to promote rereplication and senes-
cence in CDT2-depleted melanoma cells.
3.4. Pevonedistat Inhibits Melanoma Cells Through The Induction of
Rereplication and Senescence, and Elevated CDT2 Expression Renders Mel-
anoma Cells Susceptible to Pevonedistat-Induced Rereplication
The CRL4CDT2, similar to all cullin-based ligases, is regulated by
NEDD8 modiﬁcation, which is catalyzed by an enzyme cascade system
similar to ubiquitylation (Merlet et al., 2009). Pevonedistat inhibits
cullin signaling, offering a pharmacological approach for targeting mel-
anoma potentially through inhibiting CRL4CDT2 ligase activity. To test
this possibility, we treated DM93 cells with increasing doses of
pevonedistat for 24 h. This resulted in a dose-dependent increase in sev-
eral cullin ubiquitylation substrates, including CDT2, CDT1, p21 andp27,
which reached signiﬁcant levels at 1 μMdrug concentration (Fig. 4a). Al-
though CDT2 is increased by pevonedistat, it is likely to be inactive be-
cause of the de-neddylation of cullin proteins (Fig. 4a and b). Time
course analysis with 1 μM pevonedistat demonstrated early (at 3 and
Fig. 3. Deregulated stability of catalytically active SET8 and p21 promotes rereplication and senescence in melanoma cells (see also Figure S5). a. Immunoblotting of protein lysates
extracted from the indicated cancer cell lines and transfected with si-GL2 or depleted of geminin (si-geminin). Tubulin is a loading control. b. BrdU labeling and FACS analysis of DM93
melanoma cells shown in (a). c. Percentage of cells with rereplication as determined by FACS of the cells shown in (a). Data represent the average of three independent
experiments ± S.D. ***p b 0.001, calculated using Student's t-test; ns: non-signiﬁcant. d. Immunoblotting of control DM39 cells (with empty retrovirus; PMX) or ectopically expressing
the indicated CDT1 proteins from retrovirus. e. Percentage of cells with rereplication following transduction with retroviruses expressing the indicated proteins. Data represent the
average of three independent experiments ± S.D. **p b 0.01, calculated using Student's t-test. f. Immunoblotting of DM93 and VMM39 cell extract following transduction with
retrovirus expressing the indicated proteins. Tubulin is a loading control. Asterisk: cross-reactive band. g. Percentage of rereplicating DM93 or VMM39 cells treated as in (f) as
determined by FACS analysis. Data represent the average of three independent experiments ± S.D. ***p b 0.001, calculated using Student's t-test. h. Representative images of DM93
treated as in (f) and stained with β-gal to monitor senescence. i. Percentage of senescent DM93 and VMM39 cells following the expression of the indicated proteins. Data represent
the average of three independent experiments ± S.D.
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93M. Benamar et al. / EBioMedicine 10 (2016) 85–1006 h) increase in CDT1 aswell as SET8 protein and activity (H4K20mono-
methylation) followed by the appearance of p21 and p27 (Fig. 4b, and
Figure S6a and S6b). Increases in CDT1, SET8 and p21were all attributed
to increased stability as well as increase in the stability of not only
H4K20me1, but also H4K20me2 and H4K20me3 (Figure S6c–S6f).
These latter epigenetic modiﬁcations are catalyzed by the SUV4-20H1
and SUV4-20H2 methyltransferase, respectively, and have been
shown to be increased in cells with deregulated SET8 stability and con-
tribute to DNA rereplication (Abbas et al., 2010; Beck et al., 2012).
DM93 cells treated with pevonedistat accumulated spontaneous
DNA damage (increased γH2AX) and arrested in S and G2/M phases
of the cell cycle due to activated DNA damage and G2/M checkpoints
i.e. increased phosphorylation of CHK1 and CHK2, increased phosphor-
ylation of CDK1 and the accumulation of cells in S and G2 (Fig. 4b, c,
and data not shown). This signiﬁcantly inhibited melanoma cell prolif-
eration (Figure S7b and S7d), concurrently withmorphological changes
reminiscent to those induced by CDT2 depletion or deletion (Figs. 2b,
4e, 4f and Figure S2e). Consistently, ﬂow cytometry analysis showed
18% of DM93 cells exhibiting N4N DNA content within 24 h, which in-
creased to 68% by 72 h of treatment (Fig. 4c). The extent of rereplication
increased with increasing doses of pevonedistat when analyzed at 24 h,
and was observed with as low as 500 nM drug concentration (Figure
S7a). BrdU labeling illustrated that rereplication occurred within the
same cell cycle in 17 and 60% of cells when analyzed at 24 and 48 h, re-
spectively (Figure S7c). While some cells treated with pevonedistat
underwent cell death by apoptosis i.e. appearance of cleaved PARP pro-
tein and increased cells with sub-G1 DNA content (~7%), themajority of
cells underwent senescence occurring as early as 48 h post-treatment
(Fig. 4b–f).
Using clonogenic survival assays, we found that pevonedistat
inhibited the proliferation of DM93 and VMM39, at lowdrug concentra-
tions of 100 and 50 nM, respectively (Fig. 4d and Figure S4e). Cell viabil-
ity and proliferation assays demonstrated that pevonedistat effectively
inhibited all the melanoma lines tested, with VMM39 and DM13 being
the most sensitive with IC50 of 35 and 40 nM, respectively (Fig. 4g).
VMM1 melanoma cells on the other hand, were least sensitive with an
IC50 of 330 nM. Pevonedistat resulted in varying degrees of rereplication
in these cells (Fig. 4h and Figure S7f). For example, whereas
pevonedistat treatment of DM93 cells resulted in 60% of the cells under-
going rereplication at 72 h post-treatment, only 25% of VMM1 and 13.7%
of DM13 cells rereplicated their DNA. SLM2 melanoma cells with wt
BRAF, NRAS, TP53 and CDKN2A also exhibited robust rereplication with
N58% of cells with rereplication at 72 h post-treatment. Although
CDT2 expression in the various lines did not correlate signiﬁcantly
with the IC50 of pevonedistat (Fig. 4g and i), it signiﬁcantly correlated
with pevonedistat-induced rereplication (r= 0.745, p b 0.01) (Fig. 4j).
Strikingly, ectopic overexpression of wt CDT2 in two melanoma cell
lines with low expression of CDT2 (VMM1 and DM13) resulted in the
induction of statistically signiﬁcant more rereplication in response to
pevonedistat than control cells with empty virus (pMSCV) (Fig. 4k and
l). This did not occur with overexpression of a mutant CDT2 protein
(CDT2R246A), which cannot bind DDB1 and is thus incapable of assem-
bling functioning CRL4CDT2 ligase (Jin et al., 2006). This result provides
evidence that CDT2 expression directly relates to the efﬁcacy of
pevonedistat to induce rereplication in vitro through its ubiquitylation
activity. Finally, although pevonedistat induced rereplication in all the
examined melanoma lines, it induced robust senescence only in cells
with wt CDKN2A (encoding p16), with minimal impact in cells with
an inactivated CDKN2A gene (VMM1, DM13 and VMM18 cells), similar
to what is observed in si-CDT2 cells (Fig. 2i and 4m). Collectively,
these results demonstrate that pevonedistat treatment of melanoma
cells is associated with the hallmark of CRL4CDT2 inactivation observed
with CDT2 depletion or deletion. The results also demonstrate the efﬁ-
cacy of pevonedistat to inhibit melanoma in vitro, irrespective of the
BRAF/NRAS or CDKN2Amutational status, although the lattermay be im-
portant for pevonedistat-induced senescence.3.5. Transient Exposure to Pevonedistat Is Sufﬁcient to Induce Rereplication
and Permanent Growth Arrest in Melanoma Cells, but Not in Immortalized
Non-Transformed Melanocytes
To determine the relationship between the ability of pevonedistat to
induce rereplication in melanoma cells and its inhibitory activity, we
treated DM93 or VMM39 cells with pevonedistat for 4, 8, 12 or 24 h,
washed the drug extensively, and incubated cells with fresh media for
various time points. The results demonstrated that cells exposed to
pevonedistat for 4 or 8 hwere transiently inhibited, but resumed prolif-
eration 24 h later (Fig. 5a–c, and Figure S8a and S8b). This coincided
with restoration of cullin neddylation, and the destabilization of CDT1,
SET8 and p21 (Fig. 5a). In contrast, cells treated with pevonedistat for
12 or 24 h remained arrested, and exhibited 18% and 60% rereplication,
respectively when analyzed 48 h later and were senescent (Fig. 5a–c
and data not shown). The reduction in the percentage of rereplicating
cells at 48, 72 and 92 h following transient exposure for 12 or 24 h is ex-
plained by the continuous proliferation of cells that did not undergo
rereplication following drug removal. DM93 cells treated for 12 or
24 h maintained high levels of p21, but not CDT1 or SET8 (Fig. 5a), sug-
gesting that p21may be essential formaintaining the rereplication phe-
notype. Furthermore, treatment of DM93 cells with vemurafenib
induced robust G1 growth arrest and complete depletion of S-phase
cells, and inhibited pevonedistat-induced rereplication (Fig. 5d and e).
This result, and the fact that it takes at least 24 h to achieve permanent
growth inhibition, demonstrates that pevonedistat-induced
rereplication requires that cells remain in active replicative phase, and
that a sufﬁcient time of exposure (12–24 h) is necessary to permanently
arrest all cycling cells.
Unlikemelanoma cells, the treatment of PIG3Vor PIG1 immortalized
melanocytic cell lines with pevonedistat resulted in only modest inhibi-
tion of proliferation with an IC50 of N500 nM (Fig. 4g). Although the
continuous treatment of PIG3Vwith 1 μMpevonedistat inhibited prolif-
eration (Figure S8d and S8e), this was not associated with rereplication
or senescence (Figure S7c and S8g). This was not due to a lack of inhibi-
tion of CRL4CDT2, as these cells accumulated the CRL4CDT2 substrates
CDT1, p21 and SET8 (which were only transiently upregulated) as
well as other cullin substrates, such as p27, with similar kinetics as in
DM93 (Fig. 5a and Figure S8c). PIG3V melanocytes exposed to 1 μM
pevonedistat for 24 h arrested in G1, but resumed cycling following
drug removal, and this was associated with the reversal of cullin
neddylation and CRL4Cdt2 substrate accumulation, including p21 (Figure
S8c–S8f).
3.6. Pevonedistat Induces Permanent Growth Inhibition in Melanoma Cells
Through SET8- and p21-Dependent Rereplication and Senescence
The lack of signiﬁcant correlation between pevonedistat-induced
rereplication and toxicity prompted us to investigate the contribution
of rereplication and/or senescence to pevonedistat-induced toxicity.
To achieve this, we ﬁrst show that siRNA-mediated depletion of CDT1,
SET8 or p21 all inhibited pevonedistat-induced rereplication, and senes-
cence (Figure S9), similar to what we observed following CDT2 deple-
tion. Next, we utilized the CRISPR/Cas9 editing tools in an attempt to
generate melanoma cells with deletion in CDKN1A (encoding p21) or
SET8. We obtained several clones of DM93 cells, but none had biallelic
deletion of either gene (Figure S10). Although we were surprised that
none of the clones we obtained were biallelically deleted of CDKN1A,
the lack of clones with complete deletion of SET8 is consistent with
the important role of SET8 in cell viability (Oda et al., 2010; Schotta et
al., 2008). Nevertheless, several clones exhibited a loss of one allele of
CDKN1A (sg-p21-1-6), and these exhibited signiﬁcantly reduced levels
of p21 in pevonedistat-treated cells (Fig. 5f and Figure S10a–S10c).
We also obtained several clones of DM93 cells with monoallelically de-
leted SET8 (sg-SET8-1-6), and these had signiﬁcantly reduced levels of
SET8 protein (Fig. 5f and Figure S10d–S10f). The sg-SET8 cells exhibited
Fig. 4. Pevonedistat inhibits melanoma cell proliferation and induces rereplication and senescence, irrespective of the BRAFmutational status, and elevated CDT2 expression renders
melanoma cells sensitive to pevonedistat-induced rereplication (see also Figures S6 and S7). a. Immunoblotting of cell lysates following treatment with the indicated doses of
pevonedistat analyzed 24 h post-treatment. Tubulin is a loading control. b. Same as (a) except cells were treated with 1 μM pevonedistat and cells harvested at the indicated time
points following treatment. ndCullin 3: neddylated cullin 3. c. FACS analysis (PI staining) of cells treated with 1 μM pevonedistat for the indicated time points. Percentage of cells with
rereplication (NG2/M DNA content) or undergoing apoptosis (sub-G1 DNA content) is also indicated. d. Representative images of clonogenic survival assays of DM93 melanoma cells
treated with the indicated doses of pevonedistat. e. Representative phase contrast images of DM93 cells treated with DMSO (solvent) or pevonedistat (1 μM) for 24 h. f. Representative
images of DM93 cells treated with pevonedistat for 96 h, and stained with β-gal. g. Viability assays of the indicated melanoma lines and melanocytic PIG1 and PIG3V following
treatment with the indicated doses of pevonedistat and expressed as a percentage of control DMSO-treated samples. Data represent the average of three independent experiments ±
S.D. h. The percentage of melanoma lines with rereplication following treatment with 1 μM pevonedistat as analyzed by FACS at 24 or 72 h. Data represent the average of three
independent experiments ± S.D. i. Steady state CDT2 protein expression in the indicated melanoma cells as determined by immunoblotting. Tubulin is a loading control. j. Correlations
between the steady state level of CDT2 protein in various cancer cell lines shown in (i) and the DNA rereplication at 24 h post-treatment shown in (h). k. Immunoblotting of Flag-
CDT2 or FLAG-CDT2R246A proteins following their ectopic and stable expression in VMM1 or DM13 melanoma cells from retrovirus. Tubulin is a loading control. l. Percentage of cells in
(k) undergoing rereplication following pevonedistat treatment (1 μM) for 72 h, as determined by FACS analysis. Data represent the average of three independent experiments ± S.D.
*p b 0.05; **p b 0.01, calculated using Student's t-test. m. Percentage of the indicated melanoma lines undergoing senescence following treatment with 1 μM pevonedistat and
analyzed 96 h following treatment. Data represent the average of three independent experiments ± S.D.
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parental or control DM93 cells (Fig. 5i, and data not shown). Strikingly,
both p21 and SET8hypomorphic DM93 cells were signiﬁcantly resistant
to pevonedistat-induced rereplication and senescence, despite cullin
deneddylation, and the upregulation of CDT1 protein (Fig. 5f–h, and Fig-
ure S10c and S10f). This result demonstrates that increased endogenous
levels of CDT1 is not sufﬁcient to induce rereplication or senescence in
the presence of lower levels of SET8 or p21, and further suggests that
pevonedistat-induced senescence in melanoma cells is a consequence
of DNA rereplication. Given that melanoma cells with higher levels of
CDT2 are more susceptible to pevonedistat-induced rereplication (Fig.
4h–l), and only the overexpression of CRL4CDT2-resistant, but not CRL4-
CDT2-sensitive form of SET8 is sufﬁcient to trigger rereplication (Fig. 3g),
the failure of pevonedistat to induce rereplication and senescence in sg-
p21 or sg-SET8 cells highly suggest that pevonedistat-induced
rereplication and senescence in melanoma cells is mediated through
CRL4CDT2 inhibition and the stabilization of SET8 and p21 proteins.
When added continuously in culture, pevonedistat still inhibited the
proliferation of sg-p21 and sg-SET8 cells (Fig. 5i). Strikingly however,
unlike control cells (sg-control), cells with reduced expression of p21
or SET8 resumed proliferation following the cessation of pevonedistat
treatment (Fig. 5i and j). Thus, pevonedistat inhibits the proliferation
of melanoma cells through the induction of SET8- and p21-dependent
rereplication mechanism, as well as through another mechanism that
only transiently inhibits cell proliferation. The result also explains the
lack of a signiﬁcant correlation between pevonedistat-inhibitory activi-
ty (IC50) and the induction of rereplication.
3.7. Pevonedistat Exerts Anti-Melanoma Activity Through CRL4CDT2 Inhibi-
tion and Stabilization of SET8 and p21, Irrespective of BRAF/NRAS Muta-
tional Status
To examine the efﬁcacy of pevonedistat to inhibit melanoma in vivo,
we inoculated nude mice with DM93 cells and monitored tumor
growth. When tumors reached 100–150 mm3 in volume, randomized
group of mice (n = 12) were treated with DMSO or with 30 or 60 mg/
kg for 5 consecutive days for two cycles separated by 5 days of no treat-
ment (Soucy et al., 2009). Animals were weighted and monitored daily
and the drug was well tolerated (Figure S11, and data not shown). Fig.
6a demonstrates that pevonedistat signiﬁcantly suppressed DM93mel-
anoma xenografts at 30 mg/kg (p = 7.7 × 10−3) or 60 mg/kg (p =
2.3 × 10−3), but did not result in tumor regression, consistent with
the lack of signiﬁcant apoptotic effect of this drug in vitro. Tumor re-
growth was not detectable at either drug concentration as monitored
up to 10 days following the cessation of treatment. Analysis of tumor ex-
tracts of treated animals (on day 25) demonstrates that pevonedistat
inhibited cullin neddylation and resulted in the accumulation of cullin
substrates (CDT2, CDT1, and p21) and spontaneous DNA damage, and
exhibited activated checkpoints (Fig. 6b). Because SET8 protein is only
transiently increased by pevonedistat, we did not detect signiﬁcant in-
creases of SET8 in these tumor lysates at this late time point. Important-
ly, although pevonedistat (30mg/kg) signiﬁcantly inhibited the growth
of sg-control DM93 xenografts (p = 0.009), it failed to inhibit the
growth of sg-p21-1 or sg-SET8-1 DM93 xenografts (p = 0.092 and
0.66, respectively) (Fig. 6c). This result provides evidence that targeted
inactivation of the CRL4CDT2 E3 ligase, and the stabilization of its sub-
strates p21 and SET8, is the primary mechanism underlying the anti-
melanoma activity of pevonedistat in vivo.
To testwhether pevonedistat also inhibits non-BRAFmelanomas,we
established xenografts of VMM39 (withNRAS and PDGFR activatingmu-
tations) or SLM2 cells (without NRAS or BRAFmutations). Fig. 7a and b
demonstrate that the administration of pevonedistat (60mg/kg) signif-
icantly inhibited the growth of VMM39 and SLM2 xenografts (p =
1.8 × 10−5, and 2.3 × 10−3, respectively), although tumor regrowth
was apparent in these xenografts following the cessation of drug admin-
istration. Similar to DM93 xenografts, pevonedistat inhibited thedeneddylation of cullins and induced the accumulation of CDT1 and
p21 proteins in the VMM39 xenografts, even when tumors were ana-
lyzed 10 days following the cessation of treatment (Figure S11b).
Pevonedistat also inhibited, albeit to a lesser extent, the growth of
DM331 xenografts, a mutant BRAF melanoma cell line resistant to the
BRAF kinase inhibitors vemurafenib or PLX4720, a structural analogue
and precursor of vemurafenib with more potent activity in rodents
(Tsai et al., 2008) (Fig. 7c and Figure S12; and (Roller et al., 2015)). Al-
though these xenografts were nevertheless inhibited by PLX4720, the
combined administration of pevonedistat and PLX4720 resulted in syn-
ergistic inhibition (Fig. 7c). Finally, DM331 cells, as well as the BRAF-
mutant SK-MEL-24 cells, extracted ex-vivo from PLX4720-resistant tu-
mors (Roller et al., 2015), remained insensitive to vemurafenib, but
were sensitive to pevonedistat-induced rereplication and inhibition in
vitro (Fig. 7d–g). Collectively, these results demonstrate that the admin-
istration of pevonedistat as a single agent inhibits melanoma in vivo, ir-
respective of the BRAF/NRAS mutational status, synergizes with
PPLX4720 to inhibit BRAF melanoma proliferation, and effectively in-
hibits PLX4720-relapsed melanoma cell growth.
4. Discussion
We identiﬁed the CRL4CDT2 E3 ubiquitin ligase as a molecular thera-
peutic target inmelanoma. CDT2knockdownor thepharmacological in-
hibition of CRL4CDT2 activity by the neddylation inhibitor pevonedistat
inhibits melanoma cell proliferation in vitro and in vivo through the in-
duction of SET8- and p21-dependent aberrant DNA replication and the
induction of p21-dependent cellular senescence. This occurs irrespec-
tive of theBRAF orNRASmutational status. Although p16may also be in-
volved in rereplication-induced senescence, it is not essential for
pevonedistat-induced toxicity, and thus, mutational inactivation of the
CDKN2A or oncogenic activation of BRAF or NRAS, all common genetic
defects in melanoma, do not present an obstacle for the therapeutic ef-
ﬁcacy of pevonedistat. Pevonedistat was also efﬁcacious in suppressing
melanoma cells that are resistant to vemurafenib treatment in vitro and
synergized with PLX4720 to suppress mutant BRAF melanoma. It re-
mains to be determined however, whether CRL4CDT2 inhibition, or the
stabilization of SET8 or p21, contributes to the synergistic activity of
pevonedistat with PLX4720. Nevertheless, our ﬁndings suggest that
pevonedistat may be most efﬁcacious if administered along with other
melanoma inhibitors, such as vemurafenib (for BRAF melanomas), and
may also be considered as a second line therapeutic for vemurafenib-
or other BRAF kinase inhibitor-relapsed melanoma patients.
Mechanistically, we show that CRL4CDT2 is the primary target of inac-
tivation by pevonedistat inmelanoma and that its toxicity is dependent
primarily on the stabilization of the CRL4CDT2 substrates SET8 and p21
both in vitro and in vivo. The lack of a therapeutic response onmelanoma
cellswith hypomorphic expression of SET8or p21provides solid genetic
evidence that the main anti-melanoma activity of pevonedistat is asso-
ciated with the drug's ability to promote rereplication and permanent
growth inhibition through preventing SET8 and p21 proteolytic degra-
dation. Pevonedistat however, also transiently inhibits melanoma pro-
liferation through an unknown mechanism. We speculate that this
may be dependent on the accumulation of other cullin substrates and
may include the CDK2 inhibitor p27, an SCFSKP2 ubiquitylation substrate,
which is also stabilized by pevonedistat (Fig. 4a and b). This however, is
insufﬁcient to halt melanoma proliferation in the absence of SET8- and
p21-mediated cytotoxicities (Fig. 6c).
Whereas the CRL4CDT2 substrates CDT1 and p21 are independently
required to induce rereplication and senescence in melanoma cells
with inactivated CRL4CDT2, SET8 is both necessary and sufﬁcient to pro-
mote rereplication and the ensuing senescence. The exact mechanism
by which increased SET8 protein stability promotes rereplication is cur-
rently unclear, but histone H4K20 methylation may be critical for this
activity (Abbas et al., 2010; Tardat et al., 2010). The main role of p21
on the other hand, appears to halt cell cycle progression (thus
Fig. 5. Transient exposure of melanoma cells to pevonedistat induces p21- and SET8-dependent permanent growth inhibition and senescence (see also Figure S10). a. Immunoblotting of
protein extracts of DM93 cells treatedwith 1 μMpevonedistat and harvested according the schematic time line of drug addition andwithdrawal (wash out (WO); Top). Tubulin is loading
control. ndCul3: neddylatedCullin 3. b. Proliferation of DM93 cells treated according to the schematic in (a) as determinedby cell counting. Data represent the average of three independent
experiments ± S.D. c. Percentage of DM93 cells shown in (a) undergoing rereplication as determined by PI staining and FACS analysis. Data represent the average of three independent
experiments ± S.D. d. FACS analysis (PI staining) of DM93 cells treated with vemurafenib (PLX4032) for 24 h showing the induction of G1 cell cycle arrest. e. Percentage of DM93 cells
undergoing rereplication with or without vemurafenib treatment for 24 h before the addition of pevonedistat for another 48 h. Data represent the average of three independent
experiments ± S.D. f. Immunoblotting of protein lysates of individual clones of DM93 cells with hypomorphic expression of p21 (sg-p21-1) or SET8 protein (sg-SET8-1) and treated
with 1 μM pevonedistat for 48 h. g–h. Percentage of cells undergoing rereplication (g) and senescence (h) in the cells shown in (f). Data represent the average of three independent
experiments ± S.D. p-values were calculated using Student's t-test. *p b 0.05; **p b 0.01; ***p b 0.001. i. Same as in (b), but with the sg-control-1, sg-p21-1 and sg-SET8-1 DM93 cells
shown in (f). j. Same as in (c), but with the sg-control-1, sg-p21-1 and sg-SET8-1 DM93 cells shown in (f).
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Fig. 6. Pevonedistat inhibits melanoma xenografts through p21- and SET8-dependent mechanism (see also Figure S11). a. Nude mice bearing DM93 tumor xenografts were dosed by IP
administration with either vehicle (DMSO) or with the indicated doses of pevonedistat according the schedules indicated in Materials & Methods. Mean tumor volumes ± s.e.m. are
shown. n= 12 mice per group. p-values were calculated using Student's t-test; **p b 0.01. b. Immunoblotting of protein lysates of DM93 tumor xenografts from 5 randomly selected
animals of each group (a, extracted on day 25) for the indicated proteins. Tubulin is a loading control. c. Same as in (a), except control DM93 (left; sg-control), or DM93 hypomorphic
clones of p21 (sg-p21-1; middle) or SET8 (sg-SET8-1; right) were used to establish the tumor xenografts, and animals were administered pevonedistat (30 mg/kg). Mean tumor
volumes ± s.e.m. are shown. n= 12 mice per group. p-values were calculated using Student's t-test; **p b 0.01; ns: non-signiﬁcant (p N 0.05).
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the ﬁnding that p21 is critical for the induction of rereplication and se-
nescence in response to CRL4CDT2 inactivation (by si-CDT2 or
pevonedistat), and is also upregulated in rereplicating cells following
the ectopic expression of CDT1 or SET8ΔPIP, or following EMI1 depletion,
but is insufﬁcient to induce rereplication.
Although CDT1 promotes rereplication in cancer cells as demon-
strated by the robust induction of rereplication through geminin deple-
tion, we did not observe such a role in melanoma cells, likely because
CDT1 activity is restrained by cyclin A-dependent SCFSKP2 activity.
Non-physiological overexpression of CDT1 however, was sufﬁcient to
induce rereplication in melanoma cells, but this is likely to also require
SET8 and p21. This conclusion is supported by the fact that although
pevonedistat induced signiﬁcant rereplication in melanoma cells, it
failed to do so in cells with hypomorphic expression of SET8 or p21, de-
spite signiﬁcant increases in CDT1 protein. The anti-melanoma activity
of pevonedistat and its dependence on CRL4CDT2 inhibition and the in-
duction of SET8- and p21-dependent rereplication provide a stronger
link between presumed drug target (NAE) and biology than is available
for many other “targeted therapies”.
Our study also demonstrates that CDT2 is signiﬁcantly
overexpressed in melanoma, and its elevated expression correlates sig-
niﬁcantly with poor overall and disease-free patient survival. Because
elevated CDT2 expression correlates with, and renders melanoma
cells more susceptible to, pevonedistat-induced rereplication in vitro,
and given that rereplication appears to play a major role in mediating
its efﬁcacy in vivo, we speculate that pevonedistat would be mostefﬁcacious in tumors with elevated CDT2 expression. This includes not
only melanoma, but also potentially other malignancies with elevated
CDT2 expression (Figure S1).
CDT2 is not likely to function as a classical oncogene, butmay act as a
cancer-associated gene to which cancer cells become “addicted”. This is
supported by the ﬁnding that while CRL4CDT2 inactivation by
pevonedistat induces rereplication in melanoma cells, it failed to do so
in non-cancer melanocytic cells. Similarly, CDT2 depletion in non-
cancer cells failed to induce rereplication in non-cancer cells, but did
so following the ectopic expression of KRAS (Olivero et al., 2014). We
propose that CDT2 is overexpressed in melanoma cells to alleviate
replication stress that may be induced by melanoma oncogenes.
Because only transient exposure of melanoma cells to pevonedistat
is sufﬁcient to irreversibly arrest melanoma cells with the majority of
cells undergoing senescence, and this occurs only in malignantmelano-
ma cells, targeting the CRL4CDT2 ubiquitin ligase is an especially attrac-
tive therapeutic approach that is likely to be associated with only
minimal impact on normal cellular activity or cytotoxicity. Why non-
malignant melanocytes exposed to pevonedistat are only transiently
inhibited, and without undergoing robust rereplication, is not clear,
but our results support the hypothesis that non-cancer cells have addi-
tional mechanisms to guard against aberrant DNA rereplication (Abbas
et al., 2013).
In summary, our ﬁndings illustrate that the CRL4CDT2-SET8/p21 deg-
radation axis is a promising new target for inactivation in melanoma.
We provide signiﬁcant evidence for the utility of pevonedistat as an ef-
fective single-agent therapeutic for BRAF and non-BRAF cutaneous
Fig. 7. Pevonedistat inhibits melanoma xenografts irrespective of the BRAFmutational status and synergizeswith the BRAF inhibitor PLX4720 to suppress BRAFmelanoma. a-c. Nudemice
bearing VMM39 (mut-NRAS; a), SLM2 (wt NRAS/BRAF; b) or DM331 (mut-BRAF; c) tumor xenografts were dosed by IP administration (60 mg/kg) pevonedistat according the schedules
indicated in Materials & Methods. Mice with DM331 xenograft were also treated with PLX4720, or with pevonedistat and PLX4720 as described in Materials & Methods. Mean tumor
volumes ± s.e.m. are shown. n = 12 mice per group. p-values were calculated using Student's t-test; **p b 0.01; ***p b 0.001. d. Viability assays of DM331 (R1-R3) or SK-MEL-24 (R1
and R2) cells extracted ex vivo from PLX4720-resistant tumors and treated with the indicated doses of vemurafenib. DM93 cells were similarly analyzed and shown for comparison.
The results are expressed as a percentage of control DMSO-treated samples. Data represent the average of three independent experiments ± S.D. e. Immunoblotting of DM331 (R1)
and SK-MEL24 (R1) cell extracts following treatment with 1 μM pevonedistat for the indicated time in vitro. Tubulin is a loading control. f. Viability assays of DM331 (R1-R3) or SK-
MEL-24 (R1 and R2) cells treated with the indicated doses pevonedistat in vitro. The results are expressed as a percentage of control DMSO-treated samples. Data represent the
average of three independent experiments ± S.D. g. Percentage of DM331 (R1-R3) and SK-MEL-24 (R1 and R2) undergoing rereplication following treatment with 1 μM pevonedistat
for 72 h. Data represent the average of three independent experiments ± S.D.
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99M. Benamar et al. / EBioMedicine 10 (2016) 85–100melanoma, as a synergistic agent with BRAF kinase inhibitors for BRAF
melanoma, and potentially as a second line therapeutic for recurrent
melanoma following BRAF-kinase inhibitor monotherapy.
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